China-based Boan Biotech (HKG: 6955) has announced that its novel antibody BA1105 and antibody-drug conjugate (ADC) BA1301 have received orphan drug designations (ODDs) from the U.S. Food and Drug Administration (FDA). Both therapies target Claudin18.2 (CLDN18.2) for the treatment of pancreatic cancer.
BA1105 is being developed for Claudin18.2 positive advanced solid tumors and is currently in Phase I trials in China. BA1301, the company’s first ADC to enter clinical development, is also undergoing Phase I studies domestically.- Flcube.com
